TY - JOUR
T1 - Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus
T2 - Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?
AU - Barnabei, Agnese
AU - Strigari, Lidia
AU - Corsello, Andrea
AU - Paragliola, Rosa Maria
AU - Falzone, Luca
AU - Salvatori, Roberto
AU - Corsello, Salvatore Maria
AU - Torino, Francesco
N1 - Publisher Copyright:
Copyright © 2022 Barnabei, Strigari, Corsello, Paragliola, Falzone, Salvatori, Corsello and Torino.
PY - 2022/3/3
Y1 - 2022/3/3
N2 - Immune checkpoint inhibitors have improved the survival in patients affected by an increasing number of malignancies, but they may also trigger various autoimmune side-effects, including endocrinopathies. Very rarely, immune checkpoint inhibitors have been reported to cause central diabetes insipidus. However, with their expanding use, the likelihood that oncologists will face this endocrine adverse event is expected to increase. By reviewing the limited literature on central diabetes insipidus induced by immune checkpoint inhibitors, some inconsistencies emerge in the diagnosis and the management of patients presenting with this toxicity, together with difficulties related to classifying its severity. Until now, specific guidelines on the management of central diabetes insipidus induced by immune checkpoint inhibitors are lacking. In clinical practice, endocrinological consultation may relieve medical oncologists from difficulties in treating this side-effect; oncologists, however, remain responsible for its early diagnose and the management of the causative drugs. To this aim, some practical suggestions are advised for the multidisciplinary management of cancer patients presenting with central diabetes insipidus induced by immune checkpoint inhibitors.
AB - Immune checkpoint inhibitors have improved the survival in patients affected by an increasing number of malignancies, but they may also trigger various autoimmune side-effects, including endocrinopathies. Very rarely, immune checkpoint inhibitors have been reported to cause central diabetes insipidus. However, with their expanding use, the likelihood that oncologists will face this endocrine adverse event is expected to increase. By reviewing the limited literature on central diabetes insipidus induced by immune checkpoint inhibitors, some inconsistencies emerge in the diagnosis and the management of patients presenting with this toxicity, together with difficulties related to classifying its severity. Until now, specific guidelines on the management of central diabetes insipidus induced by immune checkpoint inhibitors are lacking. In clinical practice, endocrinological consultation may relieve medical oncologists from difficulties in treating this side-effect; oncologists, however, remain responsible for its early diagnose and the management of the causative drugs. To this aim, some practical suggestions are advised for the multidisciplinary management of cancer patients presenting with central diabetes insipidus induced by immune checkpoint inhibitors.
KW - diabetes insipidus
KW - endocrinopathy
KW - hypophysitis
KW - immune checkpoint inhibitors
KW - posterior pituitary
UR - http://www.scopus.com/inward/record.url?scp=85127206190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127206190&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.798517
DO - 10.3389/fonc.2022.798517
M3 - Review article
C2 - 35311088
AN - SCOPUS:85127206190
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 798517
ER -